Abstract: The invention relates to an aqueous pesticidal composition comprising a) suspended particles comprising dimpropyridaz, and b) triethylammonium chloride.

Abstract: A method and system for increasing beneficial bacteria populations in a subject's oral cavity and decreasing pathogenic bacteria to address a variety of diseases and conditions, thereby enhancing a person's oral and overall health, including through the use of oral strips that adhere to surfaces in the oral cavity and that include at least one of xylitol, Lachnospira, Veillonella, Faecalibacterium and/or Rothia bacteria, including bacteria transformed via a CRISPR system. Certain embodiments employ light to modify oral cavity bacterial populations, including the use of bioluminescent oral strips that promote the growth of beneficial bacteria and decrease pathogenic bacteria populations.

Abstract: The present invention relates to a porous material having a scaffold comprising: one or more fibroin moieties A and one or more polysaccharide moieties B, wherein A and B are directly conjugated with another without an interconnecting linker structure. Moreover, the present invention refers to a method for preparing a porous material. The present invention further relates to an injectable composition comprising a particulate porous material according to the invention and to cosmetic and therapeutic uses thereof such as facial and body re-shaping as well as regenerating tissue.

Abstract: The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Abstract: Described herein are personal care compositions, which provide—inter alia—sweat reduction. The personal care compositions described herein may comprise humectants, thickeners, alpha hydroxy acids, and a carrier; and are typically free of added aluminum-based antiperspirant actives.

Abstract: The invention relates to an antimicrobial layer material comprising a layer with a particulate biocidal active ingredient and, on top of that, a layer as transport control layer, wherein the transport control layer is depositable or has been deposited in an afterglow PE-CVD method. The invention further relates to a substrate coated with such an antimicrobial layer material, to the use of a plasma-polymeric layer deposited in an afterglow PE-CVD method as transport control layer for a particulate biocidal active ingredient, and to a method of producing an antimicrobial layer material and to a method of producing a substrate comprising an antimicrobial layer material.

Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Abstract: Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent; compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent.

Abstract: Agents, kits, and methods that utilize oxygenation to prevent and/or treat intestinal inflammation and/or infections caused by anaerobic microorganisms are provided. In several embodiments, the formulations are provided as a capsule within a capsule in order to separate an oxygen prodrug from a catalyst until the formulation is at a target site within the intestine. In several embodiments, the catalyst is provided in an excess of the oxygen prodrug. In several embodiments, the prodrug is within an inner capsule or coating and a biological material comprising a catalyst (e.g., yeast, spirulina, chlorella, etc.) surrounds the encapsulated prodrug and the biological material is within a capsule or coating. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.

Abstract: One aspect of the invention provides a method for reducing inflammation in a patient including locally administering a composition comprising a complex comprising octadecylamine surface-functionalized nanodiamonds with dexamethasone bound to octadecylamine. Another aspect of the invention provides a method for reducing inflammation in a patient comprising locally administering a composition including octadecylamine surface-functionalized nanodiamonds, wherein no therapeutic agent is bound to the nanodiamonds.

Abstract: Provided is an antibacterial liquid with excellent temporal stability in which caking due to sedimentation of solid components does not occur and with which a film capable of stably maintaining antibacterial properties can be formed, in a case of being formed into a film. Also provided are an antibacterial film formed using the antibacterial liquid, and a spray and a cloth including the antibacterial liquid. The antibacterial liquid includes an antibacterial microparticle, a binder, and a solvent, in which the antibacterial microparticle contains a silver-supporting inorganic oxide, the binder includes at least one compound having a siloxane bond, the solvent includes an alcohol and water, the concentration of solid contents is less than 5% by mass with respect to the total mass of the antibacterial liquid, and the content of the compound having a siloxane bond is 60% by mass or more with respect to the total solid content of the antibacterial liquid.

Abstract: The Dissolvable Solid Structure as described herein can be in the form of a fibrous structure comprising: (a) a polymeric structurant; (b) a high melting point fatty compound such as a fatty amphiphile, and (c) a cationic surfactant. The polymeric structurant has a weight average molecular weight of from about 10,000 to about 6,000,000 g/mol, and the components of the fibrous material form a homogenous material when molten. When water is added to the dissolvable solid structure at a ratio of about 5:1 a lamellar structure is formed.

Abstract: Described herein are zirconium oxychloride clusters comprising zirconium oxychloride and a basic amino acid. Oral care compositions comprising the same; and methods of making and using the same are also described.

Abstract: Salsola tetrandra silver nanoparticles (ST-AgNPs) can be prepared by providing a Salsola tetrandra extract and combining the Salsola tetrandra extract with silver nitrate. The mixture can be heated to complete the bio-reduction process and provide the Salsola tetrandra silver nanoparticle composition. The Salsola tetrandra silver nanoparticles can be used to treat or inhibit a fungal infection, such as invasive pulmonary aspergillosis.

Abstract: The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Abstract: Suggested is an antimicrobial mixture comprising or consisting of (a) at least one monocyclic sesquiterpene alcohol, (b) at least one active selected from the group consisting of 4-hydroxyacetophenone, sorbitan caprylate, cocamidopropyl PG-dimonium chloride phosphate, tetrasodium glutamate diacetate, glyceryl caprylate and glyceryl caprate, and optionally (c) at least one additional antimicrobial agent different from components (a) and (b).

Abstract: The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Abstract: A wearable article, a moisturizing composition and a method for preparing a wearable article have been disclosed. The wearable article includes at least a layer of a flexible material, wherein the flexible material is an elastomeric material and an inner surface of the layer of flexible material is a coated with a coating formulation comprising 1% to 7% by weight of a moisturizing composition and 93% to 99% by weight of solvent. The moisturizing composition includes 10 to 30% by weight of at least one humectant and 1.0 to 5.4% by weight of at least one antioxidant. Thereby, the present invention reduces transepidermal water loss (TEWL) and promotes skin barrier recovery.

Abstract: Disclosed is a mucoadhesive pharmaceutical composition comprising a poly-ionic complex of chitosan and a polyacrylic acid polymer. As an oral formulation, the composition has the extended retention time in the gastrointestinal tract by its mucoadhesive and swelling properties, which is useful as sustained release formulations, retentive formulations of active ingredients with limited absorption regions, and active ingredients with pH dependent solubility.